Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nirmatrelvir/Ritonavir (Paxlovid) in COVID-19 with Severe Renal Impairment
NCT05487040Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Sep 2022
- Primary completion
- Jul 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of Nirmatrelvir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Pfizer. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events (AEs) and Serious AEs (SAEs), Number of Participants With Permanent Discontinuation From Study or Study Intervention Due to Adverse Events and 5 more. Started Sep 2022; status: terminated.
02
Drugs
Nirmatrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05487040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05487040.